ABIVAX
€85.20Change from previous close: +1.25%Absolute change: +€1.05
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Cost of revenue | — | — | — | 50.8 | 45.5 |
| Gross profit | — | — | — | -50.8 | -45.5 |
| Selling, general and administrative | 72.9 | 38.9 | 28.8 | 7.5 | — |
| Research and development | 178 | 147 | 103 | 48.3 | — |
| Operating income | -246 | -173 | -127 | -51.2 | — |
| EBIT | -302 | -164 | -134 | -53.8 | — |
| EBITDA | -301 | -163 | -133 | -53.3 | — |
| Interest expense | 28.5 | 12.4 | 13.8 | 6.9 | — |
| Pre-tax income | -330 | -176 | -148 | -60.7 | — |
| Income tax | 5.8 | 0.0 | 0.0 | 0.0 | — |
| Net income | -336 | -176 | -148 | -60.7 | — |
| Net income to common shareholders | -336 | -176 | -148 | -60.7 | — |
| Basic EPS | -4.83 | -2.78 | -3.43 | -3.18 | — |
| Diluted EPS | -4.83 | -2.78 | -3.43 | -3.18 | — |
| Average shares (basic) | 69.5 | 63.3 | 43.1 | 19.1 | — |
| Average shares (diluted) | 69.5 | 63.3 | 43.1 | 19.1 | — |